Jet vaccination to clear HPV16/18 infection in cervical precancer
Official title: Jet vaccination with pBI-11 DNA to treat HPV16/18+ ASC-US/LSIL
Funded at Johns Hopkins University · NIH-11419153 · Data updated 2026-11-12
A Johns Hopkins team is testing a targeted vaccine approach to help people with persistent HPV16/18 infections clear the virus and reduce risk of cervical precancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 30, 2003 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $327,052 |
| NIH project number | 5P50CA098252-23 |
| Project ID | NIH-11419153 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with persistent HPV16/18 infection identified by cervical screening and CIN2/3 risk profile.
✕Less likely to help
Patients without persistent infection or those outside the study criteria may not benefit from this therapy.
What this research studies
This project aims to develop a therapeutic approach for people with persistent HPV16/18 infections, which are linked to cervical precancer and cancer. The team plans to use a DNA-based strategy to trigger an immune response against HPV16/18-infected cells. If successful, the therapy could reduce progression to CIN2/3 and lessen the need for surgical procedures. The work builds on understanding how CD8 T cells and other immune factors control HPV-related lesions. Participants would be adults with persistent HPV16/18 infection who meet the study criteria.
Why it matters
Potential benefit: If successful, this therapy could help clear HPV16/18 infections and prevent cervical cancer precursors, reducing surgeries and associated risks.
How similar studies have gone: Prior preventive vaccines don’t treat existing infections; this is a therapeutic approach with potential but requires clinical validation.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Hung, Chien-Fu — Johns Hopkins University
- Study coordinator: Hung, Chien-Fu
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
-
Spatially responsive mass vaccination for urban rabies
A project tests smarter placement of vaccination sites to increase mass canine rabies vaccination in cities.
-
Vaccine failure after Covid-19 vaccination in older adults
This project follows vaccinated older adults to understand who among them still gets Covid-19 and what factors make those outcomes worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.